Atara Biotherapeutics website. Photo: Pavel Kapysh/Shutterstock.com

Atara Biotherapeutics, a company that develops treatments for patients with cancer, autoimmune and viral diseases, announced Oct. 25 that its general counsel plans on leaving her role, but will remain with the company as a consultant until early April.

Mina Kim, senior vice president, corporate strategy and general counsel, was not available for comment Monday. In a news release announcing her departure, the company said a replacement has not yet been named, and the company,based in South San Francisco, will begin the process of looking for a new general counsel.

"Mina has built the legal team with both talent and capabilities. She has decided to join a private technology company and will remain in an advisory role through March 2020," president and CEO of Atara, Pascal Touchon, said in the release.

According to an SEC filing dated Oct. 25, Kim will discontinue her role as general counsel Friday. She will remain with the company as a consultant through April 10, 2020. According to the filing, she will provide a general release and waiver of claims and will be entitled to compensation of $10,000 a month from Friday to Dec. 31 of this year. Then she will be compensated $5,000 a month from Jan. 1, 2020 to Feb. 29, 2020. She will continue vesting her outstanding equity awards during the remainder of the time she is consulting with the company.

According to her Linkedin profile, Kim became general counsel at Atara in April 2018. She previously was general counsel at Sunrun, a solar panel company, in San Francisco and was vice president of legal at BBAM LLC. Kim was assistant general counsel at Williams-Sonoma Inc. and an associate at Davis Polk & Wardwell. She is a graduate of Harvard Law School.

On the same day that Kim announced her departure, Dr. Christopher Haqq, the company's chief scientific officer, also announced that he would be leaving.

"I remain a strong believer in Atara's technologies and look forward to continue to work with the company to advance its leading off-the-shelf, allogeneic T-cell immunotherapy platform and pipeline," Haqq said in a statement.